Table 2.
Summary of Differentiation Protocols for Human Pluripotent Stem Cell-Derived Pericytes
Cell source | Differentiation methods | Characterizations | References |
---|---|---|---|
ESI-017 hESCs | Spontaneous EB differentiation; EC medium | CD146, CD105, PDGFRβ | Greenwood-Goodwin et al.102 |
H9, I6 hESCs | Spontaneous EB differentiation | CD105, NG2, PDGFRβ, calponin, nestin | Dar et al.103 |
C3, KTR13 hiPSCs | |||
NL-HES4 hESCs | Mesoderm induction: BMP4, Activin A, VEGF | CD105, NG2, PDGFRβ, CD146, CD73, CD44, 30% yield; functional in cultured vascular plexus and zebrafish xenografts | Orlova et al.; Iendaltseva et al.106,120,139 |
hiPSCs | |||
H9 hESCs | Mesoderm induction: 10% serum in α-MEM; then VEGF and SB431542 in EC medium | NG2, PDGFRβ, CD73, CD44; studied the differences compared to vSMCs (SMA, SMMHC, calponin). ECM protein production, collagens and elastin, MMP2, 9, 14, migration and invasion | Wanjare et al.108 with Jamieson et al.41 |
hiPSCs | |||
H1 hESCs | Mesoderm induction: BMP4, VEGF, FGF-2 in XVIVO-15 medium; later using SB431542; CD325-CD56+ cells were sorted using FACS | The derived cells coexpressed common mesenchymal markers (CD73, CD105, CD90, and PDGFRβ) with a subset of cells defined as CD146hiCD73hi. Transcriptional similarity exists between hPSC-derived CD146++ and primary human CD146++ perivascular cells | Chin et al.111 |
UCLA3 and UCLA6 hESCs | |||
H1, H9 hESCs | Mesoderm induction: coculture with OP9 stromal layer; or with BMP4, Activin A, and FGF-2; with BMP4, CHIR99021, PDGF-BB, and Activin A | MBs differentiate into primitive PDGFRβ+CD271+CD73− mesenchymal progenitors, which give rise to proliferative PCs, SMCs, and MSCs. MB-derived PCs can be further specified to CD274+ capillary and DLK1+ arteriolar PCs | Kumar et al.110 Blanchard et al.138 |
hiPSCs | |||
H9 hESCs | Mesoderm induction: MIM-mPCs | NG2, PDGFRβ, CD13, CD146; brain specific markers VTN, FOXC1, FOXF2. FOXF2 is higher in ncPCs than mPCs Functional assay: coculture with ECs forms tube-like structures; Wnt inhibition by DKK1 reduced PAX7 expression |
Faal et al.115 |
hiPSCs from AD patients, lines AD 5, 6 (APOE4), 13, 14, 20, 22 (APOE3), 29 | Neural crest induction: Wnt activation using CHIR99021, DMEM/F12 plus B27-ncPCs | ||
H9 hESCs | Neural crest induction: Wnt activation using CHIR99021, plus SB431542, FGF2, dorsomorphin, heparin in E6 medium; use MACS sorting and 10% FBS | PDGFRβ, NG2, expressing CNN1, TAGLN, ANPEP, TBX18; brain mural markers: FOXF2, ZIC1, ABCC9, KCNJ8; functional assay: the derived cells assemble with vascular cord networks; induced BBB properties | Stebbins et al.118 |
IMR90C4 and CS03n2 iPSCs |
DKK1, Dickkopf WNT signaling pathway inhibitor 1; FBS, fetal bovine serum; MACS, magnetic-activated cell sorting; SMMHC, smooth muscle myosin heavy chain; PC, pericyte; BBB, blood–brain barrier; hiPSC, human induced pluripotent stem cell; hESC, human embryonic stem cell; FGF, fibroblast growth factor; MIM, mesodermal induction medium; BMP4, bone morphogenetic protein 4; PDGF-B, platelet-derived growth factor-B; FACS, fluorescence-activated cell sorting; VEGF, vascular endothelial growth factor; EC, endothelial cell; EB, embryoid body; PDGFRβ, platelet-derived growth factor receptor β; NG2, neural/glial antigen 2; vSMC, vascular smooth muscle cell; SMA, smooth muscle actin; hPSC, human pluripotent stem cell; MB, mesenchymoangioblast; MSC, mesenchymal stem cell; α-MEM, alpha-minimal essential medium; DMEM, Dulbecco's modified Eagle's medium.